These data suggest that not all NSCLC patients with MPE should undergo intrapleural treatment, and that the PE‐CEA: B‐CEA ratio may be an effective indicator of intrapleural treatment. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.